Transcatheter Tricuspid Valve Intervention Plus Optimized Medical Therapy Versus Optimized Medical Therapy Alone in Tricuspid Regurgitation: A Systematic Review and Meta-Analysis
en-GBde-DEes-ESfr-FR

Transcatheter Tricuspid Valve Intervention Plus Optimized Medical Therapy Versus Optimized Medical Therapy Alone in Tricuspid Regurgitation: A Systematic Review and Meta-Analysis

05/03/2026 Compuscript Ltd

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2025.0045
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Tricuspid regurgitation (TR) is common and associated with substantial morbidity and mortality. Although optimized medical therapy (OMT) can alleviate symptoms, it may be insufficient in severe cases, and surgical interventions carry considerable procedural risk, limiting their use; consequently, tricuspid transcatheter valve interventions (TTVIs) have emerged as a less invasive alternative. The authors of this article conducted a systematic search of PubMed, Scopus, and Web of Science to identify randomized clinical trials and observational studies comparing TTVI plus OMT versus OMT alone. The primary outcome was all-cause mortality, and secondary outcomes included heart failure (HF) hospitalization and a combined outcome of all-cause mortality and HF hospitalization. Eight studies (five observational and three randomized trials) comprising 4836 patients were included. Compared with OMT alone, TTVI plus OMT was associated with a significant reduction in all-cause mortality (HR = 0.59, 95% CI: 0.44–0.78, P < 0.001) and HF hospitalization (HR = 0.69, 95% CI: 0.49–0.96, P = 0.03), and it significantly reduced the combined outcome (HR = 0.59, 95% CI: 0.47–0.74, P < 0.001). However, subgroup analysis showed that the mortality benefit was driven primarily by observational studies (HR = 0.48, 95% CI: 0.37–0.61), whereas randomized trials demonstrated no significant difference (HR = 0.88, 95% CI: 0.75–1.03). Overall, TTVI combined with OMT may be associated with lower mortality and HF hospitalization compared with OMT alone, although the apparent benefit is largely derived from non-randomized evidence.
# # # # # #
CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Taher Elmozugi, Motasam Belah Al Swayah and Abdulmoez Fauzi Elmesherghi et al. Transcatheter Tricuspid Valve Intervention Plus Optimized Medical Therapy Versus Optimized Medical Therapy Alone in Tricuspid Regurgitation: A Systematic Review and Meta-Analysis. CVIA. 2026. Vol. 11(1). DOI: 10.15212/CVIA.2025.0045
Taher Elmozugi, Motasam Belah Al Swayah and Abdulmoez Fauzi Elmesherghi et al. Transcatheter Tricuspid Valve Intervention Plus Optimized Medical Therapy Versus Optimized Medical Therapy Alone in Tricuspid Regurgitation: A Systematic Review and Meta-Analysis. CVIA. 2026. Vol. 11(1). DOI: 10.15212/CVIA.2025.0045
05/03/2026 Compuscript Ltd
Regions: Europe, Ireland
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by AlphaGalileo Terms Of Use Privacy Statement